Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 7/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20820540 | 0.85 | MAPT (0.50) | NPC1CASP3RAB9ASENP7DRD4 | |
| SCHEMBL1926867 | 0.82 | RAB9A (0.47) | NPC1CASP3RAB9ASENP7DRD4 | |
| SCHEMBL13125236 | 0.81 | RAB9A (0.54) | NPC1CASP3RAB9ASENP7TSHR | |
| SCHEMBL171697 | 0.80 | HPGD (0.46) | HPGD | |
| SCHEMBL1552798 | 0.79 | HTR2A (0.51) | NPC1CASP3RAB9ASENP7TSHR | |
| SCHEMBL1552799 | 0.79 | HTR2A (0.51) | NPC1CASP3RAB9ASENP7TSHR | |
| SCHEMBL1552795 | 0.79 | HTR2A (0.51) | NPC1CASP3RAB9ASENP7TSHR | |
| SCHEMBL12800784 | 0.79 | NPC1 (0.45) | NPC1CASP3RAB9ASENP7DRD4 | |
| SCHEMBL14804190 | 0.79 | MAPT (0.51) | NPC1RAB9ADRD4ALDH1A1HPGD | |
| SCHEMBL13849692 | 0.79 | NPC1 (0.52) | NPC1RAB9AALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765764-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20130079351-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA, INC. (JP) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079351-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | MPL, JAK2, ABL1 | NPC1 2554/4885CASP3 771/4885RAB9A 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.